文献速递淋巴瘤

纵向表达谱分析识别出ABC型弥漫性大B细胞淋巴瘤中预后不良的亚组

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

研究利用38例初诊DLBCL患者的配对诊断/复发标本,分析复发时基因表达谱变化,发现80%患者COO稳定,仅1例从ABC型转为GCB型。基于复发相关基因开发的30基因判别器可在诊断时将ABC-DLBCL分为临床高危和低危亚组,并识别出PHOENIX试验中接受依鲁替尼-R-CHOP治疗且PFS和OS更优的<60岁患者群体。

要点

  • 80%患者诊断至复发COO保持稳定,仅1例从ABC型转为GCB型
  • 30基因判别器可在诊断时将ABC-DLBCL分为高危和低危亚组
  • 该特征识别出PHOENIX试验中依鲁替尼-R-CHOP治疗PFS和OS更优的<60岁患者

核心结论

  • 基于复发相关基因开发的30基因判别器可在诊断时将ABC-DLBCL分为临床高危和低危亚组,并识别出PHOENIX试验中接受依鲁替尼-R-CHOP治疗且PFS和OS更优的<60岁患者群体。

研究设计与样本

  • 利用38例初诊DLBCL患者的配对诊断/复发存档标本进行基因表达谱分析。

主要发现

  • 80%患者从诊断到复发COO保持稳定,仅1例患者从ABC型转为GCB型。
  • 复发后转录组变化提示ABC和GCB复发通过不同机制介导。
  • 基于复发相关基因开发的30基因判别器在诊断时将ABC-DLBCL分为临床高危和低危亚组。
  • 该特征识别出PHOENIX试验中接受依鲁替尼-R-CHOP治疗且PFS和OS更优的<60岁患者群体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but fell short of providing a consistent relapse-specific genetic signature. In our study, we have focused attention on the changes in GEP accompanying DLBCL relapse using archival paired diagnostic/relapse specimens from 38 de novo patients with DLBCL. COO remained stable from diagnosis to relapse in 80% of patients, with only a single patient showing COO switching from activated B-cell-like (ABC) to germinal center B-cell-like (GCB). Analysis of the transcriptomic changes that occur following relapse suggest ABC and GCB relapses are mediated via different mechanisms. We developed a 30-gene discriminator for ABC-DLBCLs derived from relapse-associated genes that defined clinically distinct high- and low-risk subgroups in ABC-DLBCLs at diagnosis in datasets comprising both population-based and clinical trial cohorts. This signature also identified a population of <60-year-old patients with superior PFS and OS treated with ibrutinib-R-CHOP as part of the PHOENIX trial. Altogether this new signature adds to the existing toolkit of putative genetic predictors now available in DLBCL that can be readily assessed as part of prospective clinical trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bewicke-Copley F, Korfi K, Araf S, et al. Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma. Blood Adv. 2023. PMID: 35947123. doi:10.1182/bloodadvances.2022007536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。